ADMA Biologics Inc (ADMA) financial statements (2021 and earlier)

Company profile

Business Address C/O ADMA BIOLOGICS, INC.
RAMSEY, NJ 07446
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments56272343151722
Cash and cash equivalents56272343101017
Short-term investments    565
Restricted cash and investments   2   
Receivables13314110
Inventory, net of allowances, customer advances and progress billings82531913532
Inventory82531913532
Other undisclosed current assets3322000
Total current assets:154864563222124
Noncurrent Assets
Operating lease, right-of-use asset4 
Property, plant and equipment42323030  3
Intangible assets, net (including goodwill)6788   
Goodwill4444   
Intangible assets, net (excluding goodwill)2345   
Deposits noncurrent assets2321000
Restricted cash and investments  44   
Deferred costs      0
Other undisclosed noncurrent assets  11  (3)
Total noncurrent assets:54414445000
Other undisclosed assets    223
TOTAL ASSETS:20812789108242427
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities191499544
Accounts payable11966322
Accrued liabilities8443222
Interest and dividends payable      0
Deferred revenue00
Debt 00 600
Deferred revenue and credits0   
Other liabilities   0   
Other undisclosed current liabilities0 0 000
Total current liabilities:20141091144
Noncurrent Liabilities
Long-term debt and lease obligation93682725121415
Long-term debt, excluding current maturities93682625121415
Capital lease obligations0 000
Liabilities, other than long-term debt2171517442
Deferred revenue and credits3332
Accounts payable and accrued liabilities0      
Deferred revenue22
Due to related parties 151515   
Other liabilities0000210
Derivative instruments and hedges, liabilities      0
Other undisclosed noncurrent liabilities411815000
Total noncurrent liabilities:99875958171917
Total liabilities:1191016968282321
Stockholders' equity
Stockholders' equity attributable to parent, including:88262040(4)16
Common stock0000000
Additional paid in capital4292912361911028875
Accumulated deficit(340)(265)(216)(151)(107)(87)(69)
Other undisclosed stockholders' equity attributable to parent   0   
Total stockholders' equity:88262040(4)16
TOTAL LIABILITIES AND EQUITY:20812789108242427

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues422917231176
Revenue, net161176
Other operating income   7   
Cost of revenue(61)(40)(42)(3)(6)(4)(4)
Cost of goods and services sold   (29)(6)(4)(4)
Other undisclosed gross profit   (26)   
Gross profit:(19)(10)(25)(6)432
Operating expenses(107)(71)(77)(62)(28)(23)(22)
Other undisclosed operating income61404229644
Operating loss:(65)(41)(60)(39)(17)(16)(16)
Nonoperating expense(11)(7)(5)(4)(2)(2)(1)
Investment income, nonoperating012   0(0)
Interest and debt expense1(10)(6)(1)(2)(1)(1)
Loss from continuing operations before equity method investments, income taxes:(75)(58)(71)(45)(22)(19)(19)
Other undisclosed income from continuing operations before income taxes    211
Loss from continuing operations before income taxes:(75)(58)(71)(45)(20)(18)(17)
Income tax benefit      1
Net loss:(75)(58)(71)(45)(20)(18)(17)
Other undisclosed net income (loss) attributable to parent(1)1061   
Net loss available to common stockholders, diluted:(76)(48)(66)(44)(20)(18)(17)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(75)(58)(71)(45)(20)(18)(17)
Comprehensive loss, net of tax, attributable to parent:(75)(58)(71)(45)(20)(18)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: